Yu-Xin Chen

List of Publications by Year
in descending order

44 papers	2,943 citations	293460 24 h-index	286692 43 g-index
44 all docs	44 docs citations	44 times ranked	4046 citing authors

#	Article	IF	Citations
1	Inhibitory Effects and Mechanism of the Combined Use of Î±-Helical Peptides HPRP-A1/HPRP-A2 and Chlorhexidine Acetate Against Bacterial and Fungal Biofilms. International Journal of Peptide Research and Therapeutics, 2021, 27, 527-542.	0.9	2
2	Novel Bradykinin Receptor Inhibitors Inhibit Proliferation and Promote the Apoptosis of Hepatocellular Carcinoma Cells by Inhibiting the ERK Pathway. Molecules, 2021, 26, 3915.	1.7	4
3	Anticancer Activity and Mechanism of Action of kla-TAT Peptide. International Journal of Peptide Research and Therapeutics, 2020, 26, 2285-2296.	0.9	3
4	Functional Synergy Of Antimicrobial Peptides And Chlorhexidine Acetate Against Gram-Negative/Gram-Positive Bacteria And A Fungus In Vitro And In Vivo . Infection and Drug Resistance, 2019, Volume 12, 3227-3239.	1.1	20
5	Coadministration of kla peptide with HPRP-A1 to enhance anticancer activity. PLoS ONE, 2019, 14, e0223738.	1.1	17
6	Research on the effect and mechanism of antimicrobial peptides <scp>HPRP</scp>â€A1/A2 work against <i>Toxoplasma gondii</i> infection. Parasite Immunology, 2019, 41, e12619.	0.7	10
7	Targeted Modification of the Cationic Anticancer Peptide HPRP-A1 with iRGD To Improve Specificity, Penetration, and Tumor-Tissue Accumulation. Molecular Pharmaceutics, 2019, 16, 561-572.	2.3	19
8	Irisin Enhances Doxorubicin-Induced Cell Apoptosis in Pancreatic Cancer by Inhibiting the PI3K/AKT/NF-ÎºB Pathway. Medical Science Monitor, 2019, 25, 6085-6096.	0.5	21
9	Co-administration of iRGD with peptide HPRP-A1 to improve anticancer activity and membrane penetrability. Scientific Reports, 2018, 8, 2274.	1.6	38
10	Synergistic effect of the pro-apoptosis peptide kla-TAT and the cationic anticancer peptide HPRP-A1. Apoptosis: an International Journal on Programmed Cell Death, 2018, 23, 132-142.	2.2	28
11	Coâ€administration of klaâ€TAT peptide and iRGD to enhance the permeability on A549 3D multiple sphere cells and accumulation on xenograft mice. Chemical Biology and Drug Design, 2018, 92, 1567-1575.	1.5	13
12	Irisin inhibits pancreatic cancer cell growth via the AMPK-mTOR pathway. Scientific Reports, 2018, 8, 15247.	1.6	78
13	Enantiomeric Effect of d-Amino Acid Substitution on the Mechanism of Action of Î±-Helical Membrane-Active Peptides. International Journal of Molecular Sciences, 2018, 19, 67.	1.8	14
14	Role of Disulfide Bonds in Activity and Stability of Tigerinin-1R. International Journal of Molecular Sciences, 2018, 19, 288.	1.8	0
15	Effects and Molecular Mechanism of GST-Irisin on Lipolysis and Autocrine Function in 3T3-L1 Adipocytes. PLoS ONE, 2016, 11, e0147480.	1.1	41
16	Specificity and mechanism of action of alpha-helical membrane-active peptides interacting with model and biological membranes by single-molecule force spectroscopy. Scientific Reports, 2016, 6, 29145.	1.6	12
17	The relationships of irisin with bone mineral density and body composition in PCOS patients. Diabetes/Metabolism Research and Reviews, 2016, 32, 421-428.	1.7	35
18	Prokaryotic expression and antimicrobial mechanism of XPF-St7-derived Î±-helical peptides. Journal of Peptide Science, 2015, 21, 46-52.	0.8	3

#	Article	IF	Citations
19	Two hits are better than one: synergistic anticancer activity of Î±-helical peptides and doxorubicin/epirubicin. Oncotarget, 2015, 6, 1769-1778.	0.8	33
20	In vitro Characterization of the Rapid Cytotoxicity of Anticancer Peptide HPRP-A2 through Membrane Destruction and Intracellular Mechanism against Gastric Cancer Cell Lines. PLoS ONE, 2015, 10, e0139578.	1.1	18
21	Alpha-Helical Cationic Anticancer Peptides: A Promising Candidate for Novel Anticancer Drugs. Mini-Reviews in Medicinal Chemistry, 2015, 15, 73-81.	1.1	91
22	Effects and mechanisms of the secondary structure on the antimicrobial activity and specificity of antimicrobial peptides. Journal of Peptide Science, 2015, 21, 561-568.	0.8	27
23	Prokaryotic expression and mechanism of action of Î±-helical antimicrobial peptide A20L using fusion tags. BMC Biotechnology, 2015, 15, 69.	1.7	15
24	Production of an Antimicrobial Peptide <scp>AN</scp>5â€1 in <i>Escherichia coli</i> and its Dual Mechanisms Against Bacteria. Chemical Biology and Drug Design, 2015, 85, 598-607.	1.5	14
25	TAT Modification of Alpha-Helical Anticancer Peptides to Improve Specificity and Efficacy. PLoS ONE, 2015, 10, e0138911.	1.1	40
26	Effects of Single Amino Acid Substitution on the Biophysical Properties and Biological Activities of an Amphipathic Î±-Helical Antibacterial Peptide Against Gram-Negative Bacteria. Molecules, 2014, 19, 10803-10817.	1.7	15
27	Tryptophan as a Probe to Study the Anticancer Mechanism of Action and Specificity of Î±-Helical Anticancer Peptides. Molecules, 2014, 19, 12224-12241.	1.7	26
28	Role of helicity of Î±-helical antimicrobial peptides to improve specificity. Protein and Cell, 2014, 5, 631-642.	4.8	93
29	Structureâ€guided RPâ€HPLC chromatography of diastereomeric <i>Î±</i>â€helical peptide analogs substituted with single amino acid stereoisomers. Biomedical Chromatography, 2014, 28, 511-517.	0.8	6
30	Comparison on effect of hydrophobicity on the antibacterial and antifungal activities of Î±-helical antimicrobial peptides. Science China Chemistry, 2013, 56, 1307-1314.	4.2	28
31	Role of Helicity on the Anticancer Mechanism of Action of Cationic-Helical Peptides. International Journal of Molecular Sciences, 2012, 13, 6849-6862.	1.8	39
32	The study of single anticancer peptides interacting with HeLa cell membranes by single molecule force spectroscopy. Nanoscale, 2012, 4, 1283.	2.8	20
33	Inhibitory effects and mechanisms of physiological conditions on the activity of enantiomeric forms of an Î±-helical antibacterial peptide against bacteria. Peptides, 2011, 32, 1488-1495.	1.2	90
34	Studies on Mechanism of Action of Anticancer Peptides by Modulation of Hydrophobicity Within a Defined Structural Framework. Molecular Cancer Therapeutics, 2011, 10, 416-426.	1.9	163
35	Alpha-helical cationic antimicrobial peptides: relationships of structure and function. Protein and Cell, 2010, 1, 143-152.	4.8	407
36	Structure-guided de novo design of Î±-helical antimicrobial peptide with enhanced specificity. Pure and Applied Chemistry, 2010, 82, 243-257.	0.9	23

#	Article	IF	Citations
37	HPLC Analysis and Purification of Peptides. Methods in Molecular Biology, 2007, 386, 3-55.	0.4	36
38	Role of Peptide Hydrophobicity in the Mechanism of Action of Î±-Helical Antimicrobial Peptides. Antimicrobial Agents and Chemotherapy, 2007, 51, 1398-1406.	1.4	587
39	Preparative reversed-phase high-performance liquid chromatography collection efficiency for an antimicrobial peptide on columns of varying diameters (1mm to 9.4mm I.D.). Journal of Chromatography A, 2007, 1140, 112-120.	1.8	43
40	Comparison of Biophysical and Biologic Properties of alpha-Helical Enantiomeric Antimicrobial Peptides. Chemical Biology and Drug Design, 2006, 67, 162-173.	1.5	113
41	Rational Design of Î±-Helical Antimicrobial Peptides with Enhanced Activities and Specificity/Therapeutic Index. Journal of Biological Chemistry, 2005, 280, 12316-12329.	1.6	518
42	Comparison of reversed-phase liquid chromatography and hydrophilic interaction/cation-exchange chromatography for the separation of amphipathic Î±-helical peptides with l- and d-amino acid substitutions in the hydrophilic face. Journal of Chromatography A, 2003, 1009, 61-71.	1.8	35
43	Temperature profiling of polypeptides in reversed-phase liquid chromatography. Journal of Chromatography A, 2003, 1009, 29-43.	1.8	51
44	Temperature selectivity effects in reversed-phase liquid chromatography due to conformation differences between helical and non-helical peptides. Journal of Chromatography A, 2003, 1010, 45-61.	1.8	54